The climate impact of flights taken by the super-rich rose sharply from 2019 to 2023, fuelling calls for a carbon tax on private aviation

Title: Sunglasses Rival Lotions as Vital for Safety
Category: Health News
Created: 8/20/2010 12:10:00 PM
Last Editorial Review: 8/23/2010 12:00:00 AM

Title: Survival Rates Better for Certain Heart Transplant Patients
Category: Health News
Created: 8/24/2010 6:10:00 PM
Last Editorial Review: 8/25/2010 12:00:00 AM

Title: Survival More Likely With Exercise-Related Cardiac Arrest: Study
Category: Health News
Created: 8/30/2012 6:05:00 PM
Last Editorial Review: 8/31/2012 12:00:00 AM

Title: Blood Pressure Drugs Linked to Longer Ovarian Cancer Survival
Category: Health News
Created: 8/24/2015 12:00:00 AM
Last Editorial Review: 8/25/2015 12:00:00 AM

Title: Oxygen Therapy Doesn't Boost Heart Attack Survival
Category: Health News
Created: 8/30/2017 12:00:00 AM
Last Editorial Review: 8/31/2017 12:00:00 AM

Title: Scientists Challenge Key Survival Stat Cited by U.S. Officials in Plasma Approval
Category: Health News
Created: 8/25/2020 12:00:00 AM
Last Editorial Review: 8/25/2020 12:00:00 AM

Title: Blood Pressure Meds Could Improve Survival in COVID-19 Patients
Category: Health News
Created: 8/24/2020 12:00:00 AM
Last Editorial Review: 8/25/2020 12:00:00 AM

Title: 9 in 10 Americans Want Their Health Info Kept Private
Category: Health News
Created: 8/2/2022 12:00:00 AM
Last Editorial Review: 8/2/2022 12:00:00 AM

Aberrant type 2 inflammatory responses are the underlying cause of the pathophysiology of allergic asthma, allergic rhinitis, and other atopic diseases, with an alarming prevalence in relevant parts of the Western world. A bulk of evidence points out the important role of the DP2 receptor in these inflammation processes. A screening of different polyunsaturated fatty acids at a fluorescence resonance energy transfer–based DP2 receptor conformation sensor expressed in human embryonic kidney (HEK) cells revealed an agonistic effect of the prostaglandin (PG)-D₂ precursor arachidonic acid on DP2 receptor activity of about 80% of the effect induced by PGD₂. In a combination of experiments at the conformation sensor and using a bioluminescence resonance energy transfer–based G protein activation sensor expressed together with DP2 receptor wild type in HEK cells, we found that arachidonic acid acts as a direct activator of the DP2 receptor, but not the DP1 receptor, in a concentration range considered physiologically relevant. Pharmacological inhibition of cyclooxygenases and lipoxygenases as well as cytochrome P450 did not lead to a diminished arachidonic acid response on the DP2 receptor, confirming a direct action of arachidonic acid on the receptor.

G protein–coupled receptors (GPCRs) couple to heterotrimeric G proteins, comprised of α and β subunits, to convert extracellular signals into activation of intracellular signaling pathways. Canonically, GPCR-mediated activation results in the exchange of GDP for GTP on G protein α subunits (Gα) and the dissociation of Gα-GTP and G protein β subunits (Gβ), both of which can regulate a variety of signaling pathways. Hydrolysis of bound GTP by Gα returns the protein to Gα-GDP and allows reassociation with Gβ to reform the inactive heterotrimer. Naturally occurring mutations in Gα have been found at conserved glutamine and arginine amino acids that disrupt the canonical G protein cycle by inhibiting GTP hydrolysis, rendering these mutants constitutively active. Interestingly, these dysregulated Gα mutants are found in many different cancers due to their ability to sustain aberrant signaling without a need for activation by GPCRs. This review will highlight an increased recognition of the prevalence of such constitutively activating Gα mutations in cancers and the signaling pathways activated. In addition, we will discuss new knowledge regarding how these constitutively active Gα are regulated, how different mutations are biochemically distinct, and how mutationally activated Gα are unique compared with GPCR-activated Gα. Lastly, we will discuss recent progress in developing inhibitors directly targeting constitutively active Gα mutants.

ABSTRACTThe private health care sector is an important source of service delivery in low- and middle-income countries (LMICs). Yet, the private sector remains fragmented, making it difficult for health system actors to support and ensure the availability of quality health care services. In global health programs, social franchising is one model used to engage and organize the private health care sector. Two social franchise networks, ProFam in West Africa and Tunza in East and Central Africa, provide health care through branded networks of facilities. However, these social franchise networks include a limited number of private health care facilities, and in fragile contexts, like Burundi and Mali, they have faced challenges in integrating with national health systems. The MOMENTUM Private Healthcare Delivery (MPHD) project in Burundi and Mali sought to expand the number of health facilities it engaged beyond the existing ProFam and Tunza networks. The expansion aimed to help improve service quality in more private facilities while advancing localization and reducing fragmentation for improved stewardship by health system actors. MPHD achieved this expansion by removing barriers for private health facilities to join inclusive, nonbranded networks and engaging local partners to build and maintain these networks. We share lessons learned regarding the growing role of local organizations as actors within mixed health systems and provide insights on strengthening stewardship of the increasingly heterogeneous private health care delivery sector in LMICs, particularly in fragile settings.

Mitochondrial dysfunction is a hallmark of many genetic neurodegenerative diseases, but therapeutic options to reverse mitochondrial dysfunction are limited. While recent studies support the possibility of improving mitochondrial fusion/fission dynamics and motility to correct mitochondrial dysfunction and resulting neurodegeneration in Charcot-Marie-Tooth disease (CMT) and other neuropathies, the clinical utility of reported compounds and relevance of preclinical models are uncertain. Here, we describe motor and sensory neuron dysfunction characteristic of clinical CMT type 2 A in a CRISPR/Casp-engineered Mfn2 Thr105Met (T105M) mutant knock-in mouse. We further demonstrate that daily oral treatment with a novel mitofusin activator derived from the natural product piperine can reverse these neurologic phenotypes. Piperine derivative 8015 promoted mitochondrial fusion and motility in Mfn2-deficient cells in a mitofusin-dependent manner and reversed mitochondrial dysfunction in cultured fibroblasts and reprogrammed motor neurons from a human CMT2A patient carrying the MFN2 T105M mutation. Like previous mitofusin activators, 8015 exhibited stereospecific functionality, but the more active stereoisomer, 8015-P2, is unique in that it has subnanomolar potency and undergoes entero-hepatic recirculation which extends its in vivo half-life. Daily administration of 8015-P2 to Mfn2 T105M knock-in mice for 6 weeks normalized neuromuscular and sensory dysfunction and corrected histological/ultrastructural neurodegeneration and neurogenic myoatrophy. These studies describe a more clinically relevant mouse model of CMT2A and an improved mitofusin activator derived from piperine. We posit that 8015-P2 and other piperine derivatives may benefit CMT2A or other neurodegenerative conditions wherein mitochondrial dysdynamism plays a contributory role.

Oxidative stress, fibrosis, and inflammasome activation from advanced glycation end product (AGE)–receptor of advanced glycation end product (RAGE) interaction contribute to diabetic cardiomyopathy (DCM) formation and progression. Our study revealed the impact of β-caryophyllene (BCP) on activating cannabinoid type 2 receptors (CB2Rs) against diabetic complication, mainly cardiomyopathy and investigated the underlying cell signaling pathways in mice. The murine model of DCM was developed by feeding a high-fat diet with streptozotocin injections. After the development of diabetes, the animals received a 12-week oral BCP treatment at a dose of 50 mg/kg/body weight. BCP treatment showed significant improvement in glucose tolerance and insulin resistance and enhanced serum insulin levels in diabetic animals. BCP treatment effectively reversed the heart remodeling and restored the phosphorylated troponin I and sarcoplasmic/endoplasmic reticulum Ca2+ ATPase 2a expression. Ultrastructural examination showed reduced myocardial cell injury in DCM mice treated with BCP. The preserved myocytes were found to be associated with reduced expression of AGE/RAGE in DCM mice hearts. BCP treatment mitigated oxidative stress by inhibiting expression of NADPH oxidase 4 and activating phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/nuclear factor erythroid 2–related factor 2 (Nrf2) signaling. Also, BCP suppressed cardiac fibrosis and endothelial-to-mesenchymal transition in DCM mice by inhibiting transforming growth factor β (TGF-β)/suppressor of mothers against decapentaplegic (Smad) signaling. Further, BCP treatment suppressed nucleotide-binding domain, leucine-rich–containing family, pyrin domain–containing-3 (NLRP3) inflammasome activation in DCM mice and alleviated cellular injury to the pancreatic tissues evidenced by significant elevation of the number of insulin-positive cells. To demonstrate a CB2R-dependent mechanism of BCP, another group of DCM mice were pretreated with AM630, a CB2R antagonist. AM630 was observed to abrogate the beneficial effects of BCP in DCM mice. Taken together, BCP demonstrated the potential to protect the myocardium and pancreas of DCM mice mediating CB2R-dependent mechanisms.

Chronic pain conditions affect nearly 20% of the population in the United States. Current medical interventions, such as opioid drugs, are effective at relieving pain but are accompanied by many undesirable side effects. This is one reason increased numbers of chronic pain patients have been turning to Cannabis for pain management. Cannabis contains many bioactive chemical compounds; however, current research looking into lesser-studied minor cannabinoids in Cannabis lacks uniformity between experimental groups and/or excludes female mice from investigation. This makes it challenging to draw conclusions between experiments done with different minor cannabinoid compounds between laboratories or parse out potential sex differences that could be present. We chose five minor cannabinoids found in lower quantities within Cannabis: cannabinol (CBN), cannabidivarin (CBDV), cannabigerol (CBG), 8-tetrahydrocannabinol (8-THC), and 9-tetrahydrocannabivarin (THCV). These compounds were then tested for their cannabimimetic and pain-relieving behaviors in a cannabinoid tetrad assay and a chemotherapy-induced peripheral neuropathy (CIPN) pain model in male and female CD-1 mice. We found that the minor cannabinoids we tested differed in the cannabimimetic behaviors evoked, as well as the extent. We found that CBN, CBG, and high-dose 8-THC evoked some tetrad behaviors in both sexes, while THCV and low-dose 8-THC exhibited cannabimimetic tetrad behaviors only in females. Only CBN efficaciously relieved CIPN pain, which contrasts with reports from other researchers. Together these findings provide further clarity to the pharmacology of minor cannabinoids and suggest further investigation into their mechanism and therapeutic potential.

⁹-Tetrahydrocannabinol (THC) is a psychoactive phytocannabinoid found in the Cannabis sativa plant. THC is primarily metabolized into 11-hydroxy-⁹-tetrahydrocannabinol (11-OH-THC) and 11-nor-9-carboxy-⁹-tetrahydrocannabinol (COOH-THC), which may themselves be psychoactive. There is very little research-based evidence concerning the pharmacokinetics and pharmacodynamics of 11-OH-THC as an individual compound. Male C57BL/6 mice were treated with THC or 11-OH-THC via intraperitoneal injection, tail vein intravenous injection, or oral gavage, and whole-blood compound levels were measured to determine pharmacokinetic parameters [C_max, time to C_max (T_max), elimination half-life, area under the curve, apparent volume of distribution, systemic clearance, terminal rate constant, and absolute bioavailability] while also monitoring changes in catalepsy, body temperature, and nociception. 11-OH-THC achieved a T_max at 30 minutes for all routes of administration. The maximum concentration at 30 minutes was not different between intravenous and intraperitoneal routes, but the oral gavage C_max was significantly lower. THC had a 10-minute time to the maximum concentration, which was the first blood collection time point, for intravenous and intraperitoneal and 60 minutes for oral gavage, with a lower C_max for intraperitoneal and oral gavage compared with intravenous. When accounting for circulating compound levels and ED₅₀ responses, these data suggest that 11-OH-THC was 153% as active as THC in the tail-flick test of nociception and 78% as active as THC for catalepsy. Therefore, 11-OH-THC displayed equal or greater activity than the parent compound THC, even when accounting for pharmacokinetic differences. Thus, the THC metabolite 11-OH-THC likely plays a critical role in the bioactivity of cannabis; understanding its activity when administered directly will aid in the interpretation of future animal and human studies.

Chronic hypertension leads to injury and fibrosis in major organs. Fibroblast activation protein (FAP) is one of key molecules in tissue fibrosis, and ⁶⁸Ga-labeled FAP inhibitor-46 (FAPI46) PET is a recently developed method for evaluating FAP. The aim of this study was to evaluate FAP expression and fibrosis in a hypertension model and to test the feasibility of ⁶⁸Ga-FAPI46 PET in hypertension. Methods: Hypertension was induced in mice by angiotensin II infusion for 4 wk. ⁶⁸Ga-FAPI46 biodistribution studies and PET scanning were conducted at 1, 2, and 4 wk after hypertension modeling, and uptake in the major organs was measured. The FAP expression and fibrosis formation of the heart and kidney tissues were analyzed and compared with ⁶⁸Ga-FAPI46 uptake. Subgroups of the hypertension model underwent angiotensin receptor blocker administration and high-dose FAPI46 blocking, for comparison. As a preliminary human study, ⁶⁸Ga-FAPI46 PET images of lung cancer patients were analyzed and compared between hypertension and control groups. Results: Uptake of ⁶⁸Ga-FAPI46 in the heart and kidneys was significantly higher in the hypertension group than in the sham group as early as week 1 and decreased after week 2. The uptake was specifically blocked in the high-dose blocking study. Immunohistochemistry also revealed FAP expression in both heart and kidney tissues. However, overt fibrosis was observed in the heart, whereas it was absent from the kidneys. The angiotensin receptor blocker–treated group showed lower uptake in the heart and kidneys than did the hypertension group. In the pilot human study, renal uptake of ⁶⁸Ga-FAPI46 significantly differed between the hypertension and control groups. Conclusion: In hypertension, FAP expression is increased in the heart and kidneys from the early phases and decreases over time. FAP expression appears to represent fibrosis activity preceding or underlying fibrotic tissue formation. ⁶⁸Ga-FAPI46 PET has potential as an effective imaging method for evaluating FAP expression in progressive fibrosis by hypertension.

Intrapatient intermetastatic heterogeneity (IIH) has been demonstrated in metastatic castration-resistant prostate cancer (mCRPC) patients and is of the utmost importance for radiopharmaceutical therapy (RPT) eligibility. This study was designed to determine the prevalence of IIH and RPT eligibility in mCRPC patients through a triple-tracer PET imaging strategy. Methods: This was a multisite prospective observational study in which mCRPC patients underwent both ¹⁸F-FDG and ⁶⁸Ga-prostate-specific membrane antigen (PSMA)–617 PET/CT scans. A third scan with ⁶⁸Ga-DOTATATE, a potential biomarker of neuroendocrine differentiation, was performed if an ¹⁸F-FDG–positive/⁶⁸Ga-PSMA–negative lesion was found. Per-tracer lesion positivity was defined as having an uptake at least 50% above that of the liver. IIH prevalence was defined as the percentage of participants having at least 2 lesions with discordant features on multitracer PET. Results: IIH was observed in 81 patients (82.7%), and at least 1 ¹⁸F-FDG–positive/⁶⁸Ga-PSMA–negative lesion was found in 45 patients (45.9%). Of the 37 participants who also underwent ⁶⁸Ga-DOTATATE PET/CT, 6 (16.2%) had at least 1 ⁶⁸Ga-DOTATATE–positive lesion. In total, 12 different combinations of lesion imaging phenotypes were observed. On the basis of our prespecified criteria, 52 (53.1%) participants were determined to be eligible for PSMA RPT, but none for DOTATATE RPT. Patients with IIH had a significantly shorter median overall survival than patients without IIH (9.5 mo vs. not reached; log-rank P = 0.03; hazard ratio, 2.7; 95% CI, 1.1–6.8). Conclusion: Most mCRPC patients showed IIH, which was associated with shorter overall survival. On the basis of a triple-tracer PET approach, multiple phenotypic combinations were found. Correlation of these imaging phenotypes with genomics and treatment response will be relevant for precision medicine.

Take-Two Interactive have sold their publishing label Private Division to an unnamed party, along with five of Private Division's "live and unreleased titles". The GTA 6 publisher have also finally confirmed that they have shut down OlliOlli World and Rollerdrome devs Roll7 together with Kerbal Space Program 2 creators Intercept Games, months after performing mass layoffs at both studios.

Read more

I first played Taiko no Tatsujin in an arcade (in Japan, because I am very cool), where it's controlled by hitting a recreation of an actual taiko drum. It was fun enough that I wish there was a taiko drum peripheral available for PC now the series is on our platform.

Taiko no Tatsujin: Rhythm Festival is out now via Steam, where it offers over 70 songs to drum through, and a subscription service through which to unlock over 700 more. Maybe I should try to get my Donkey Konga drums working on PC, but I'll probably settle for playing it with a gamepad.

Read more

The success of the all-civilian spacewalk on SpaceX’s Polaris Dawn mission shows that private space flight is starting to catch up with government space agencies

The books, TV, games and more that New Scientist staff have enjoyed this week

The US Census Bureau processes data before publishing it in order to keep personal information private – but a new approach could maintain the same privacy while improving accuracy

Treat yourself to a Becky Lynch book signing, games with the Dropout stars, Kevin Smith’s Dogma, and so much more!

Ronnie O'Sullivan has agreed to compete in new snooker events.

There has been another shock at the Grand Slam of Darts.

The woke and overcommitted military of the last couple decades has had a hard time recruiting. We are ripe for a change.

Kurt “CyberGuy" Knutsson says there’s been a rise in cybercriminal services using hacked police and government emails to send subpoenas and data requests to U.S. companies.

The company behind Pornhub and other popular pornographic sites broke Canadian privacy law by allowing intimate images to be shared on its websites without the direct knowledge or consent of everyone depicted, the federal privacy commissioner has ruled. The Office of the Privacy Commissioner’s (OPC) investigation into Aylo (formerly MindGeek), one of the world’s largest […]

Facing an unprecedented crisis, IT World Canada, a beacon of technology journalism, is on the brink of closure. This poses a critical question: Without IT World Canada, who will narrate Canada’s tech story? After decades of serving the Canadian tech industry, IT World Canada needs help to survive. As of midnight tonight, the company is […]

The spy writing star, whose series has become a huge television hit starring Gary Oldman, is to chair the Theakston Old Peculier Crime Writing Festival 2025

Media outlets fear being dragged in to coronial inquests and forced to defend themselves whenever they report deaths.

Last week the organization tasked with running the the biggest chunk of U.S. CHIPS Act’s US $13 billion R&D program made some significant strides: The National Semiconductor Technology Center (NSTC) released a strategic plan and selected the sites of two of three planned facilities and released a new strategic plan. The locations of the two sites—a “design and collaboration” center in Sunnyvale, Calif., and a lab devoted to advancing the leading edge of chipmaking, in Albany, N.Y.—build on an existing ecosystem at each location, experts say. The location of the third planned center—a chip prototyping and packaging site that could be especially critical for speeding semiconductor startups—is still a matter of speculation.

“The NSTC represents a once-in-a-generation opportunity for the U.S. to accelerate the pace of innovation in semiconductor technology,” Deirdre Hanford, CEO of Natcast, the nonprofit that runs the NSTC centers, said in a statement. According to the strategic plan, which covers 2025 to 2027, the NSTC is meant to accomplish three goals: extend U.S. technology leadership, reduce the time and cost to prototype, and build and sustain a semiconductor workforce development ecosystem. The three centers are meant to do a mix of all three.

New York gets extreme ultraviolet lithography

NSTC plans to direct $825 million into the Albany project. The site will be dedicated to extreme ultraviolet lithography, a technology that’s essential to making the most advanced logic chips. The Albany Nanotech Complex, which has already seen more than $25 billion in investments from the state and industry partners over two decades, will form the heart of the future NSTC center. It already has an EUV lithography machine on site and has begun an expansion to install a next-generation version, called high-NA EUV, which promises to produce even finer chip features. Working with a tool recently installed in Europe, IBM, a long-time tenant of the Albany research facility, reported record yields of copper interconnects built every 21 nanometers, a pitch several nanometers tighter than possible with ordinary EUV.

“It’s fulfilling to see that this ecosystem can be taken to the national and global level through CHIPS Act funding,” said Mukesh Khare, general manager of IBM’s semiconductors division, speaking from the future site of the NSTC EUV center. “It’s the right time, and we have all the ingredients.”

While only a few companies are capable of manufacturing cutting edge logic using EUV, the impact of the NSTC center will be much broader, Khare argues. It will extend down as far as early-stage startups with ideas or materials for improving the chipmaking process “An EUV R&D center doesn’t mean just one machine,” says Khare. “It needs so many machines around it… It’s a very large ecosystem.”

Silicon Valley lands the design center

The design center is tasked with conducting advanced research in chip design, electronic design automation (EDA), chip and system architectures, and hardware security. It will also host the NSTC’s design enablement gateway—a program that provides NSTC members with a secure, cloud-based access to design tools, reference processes and designs, and shared data sets, with the goal of reducing the time and cost of design. Additionally, it will house workforce development, member convening, and administration functions.

Situating the design center in Silicon Valley, with its concentration of research universities, venture capital, and workforce, seems like the obvious choice to many experts. “I can’t think of a better place,” says Patrick Soheili, co-founder of interconnect technology startup Eliyan, which is based in Santa Clara, Calif.

Abhijeet Chakraborty, vice president of engineering in the technology and product group at Silicon Valley-based Synopsys, a leading maker of EDA software, sees Silicon Valley’s expansive tech ecosystem as one of its main advantages in landing the NSTC’s design center. The region concentrates companies and researchers involved in the whole spectrum of the industry from semiconductor process technology to cloud software.

Access to such a broad range of industries is increasingly important for chip design startups, he says. “To design a chip or component these days you need to go from concept to design to validation in an environment that takes care of the entire stack,” he says. It’s prohibitively expensive for a startup to do that alone, so one of Chakraborty’s hopes for the design center is that it will help startups access the design kits and other data needed to operate in this new environment.

Packaging and prototyping still to come

A third promised center for prototyping and packaging is still to come. “The big question is where does the packaging and prototyping go?” says Mark Granahan, cofounder and CEO of Pennsylvania-based power semiconductor startup Ideal Semiconductor. “To me that’s a great opportunity.” He points out that because there is so little packaging technology infrastructure in the United States, any ambitious state or region should have a shot at hosting such a center. One of the original intentions of the act, after all, was to expand the number of regions of the country that are involved in the semiconductor industry.

But that hasn’t stopped some already tech-heavy regions from wanting it. “Oregon offers the strongest ecosystem for such a facility,” a spokesperson for Intel, whose technology development is done there. “The state is uniquely positioned to contribute to the success of the NSTC and help drive technological advancements in the U.S. semiconductor industry.”

As NSTC makes progress, Granahan’s concern is that bureaucracy will expand with it and slow efforts to boost the U.S. chip industry. Already the layers of control are multiplying. The Chips Office at the National Institute of Standards and Technology executes the Act. The NSTC is administered by the nonprofit Natcast, which directs the EUV center, which is in a facility run by another nonprofit, NY CREATES. “We want these things to be agile and make local decisions.”

Ars speaks with users and partners unhappy with Broadcom's changes.

1. Study reveals how 3D environments affect bacterial growth and survival  The Hindu
2. 3D environments influence bacterial growth & survival  The Times of India
3. Shape Matters: New Research Reveals Impact of 3D Environments on Bacterial Growth  Research Matters
4. Study reveals role of 3D environments in influencing bacterial survival and growth  Bangalore Mirror

Kannada superstar Shivarajkumar, who is awaiting the release of his much-anticipated film ‘Bhairathi Ranagal’, has said that he is set to undergo a surgery for his illness

The annual voyage into European cinema set sail at the 29th European Union Film Festival’s opening night, where Delhi’s cinephiles huddled in eager clusters at the India Habitat Centre, in feverish anticipation of the Italian Palme D’or nominee

Peruvanam Satheesan Marar recalls his initiation into the percussion ensemble and how he gained expertise in playing different instruments

The 90-second trailer, which was delayed several times before being released, offers minimal details but hints at themes of prophecy, betrayal, and resurrection

The inaugural Red Lorry Film Festival in 2024 saw over 100 international films across various categories and languages

The 6th edition of the Dehradun Literature Festival held at Doon International School, Curzon Road, had Imtiaz Ali talking about the raison d’etre behind storytelling

​​​​​​​Jocelyne Larocque scored less than 4 minutes into the game, Sarah Nurse added a goal midway through the first period and Canada cruised to a 4-1 win over the United States in Boston on Sunday to take a 2-1 lead in the five-game Rivalry Series.

Canada’s privacy commissioner has launched an investigation into the World Anti-Doping Agency (WADA) and “its handling of biological samples collected from athletes.”

Finding regulatory violations in two private hospitals operating in the twin cities of Hyderabad and Secunderabad, the Telangana drugs control administration (DCA) has issued advisories to all the private hospitals in the state mandating strict obtainment of NDPS licence (NDPS Form II) from the DCA to purchase and sell NDPS drugs.

• Johnson & Johnson Innovative Medicines gives a peek inside its $43 billion gross-to-net bubble

• Optum Rx joins the private label biosimilar bandwagon

• Biosimilars boom for provider-administered drugs

• Fresh evidence of how copay accumulators hurt patients

There’s still time to request an invite to the inaugural Drug Channels Leadership Forum. Attendance will be highly limited. We have already begun extending invitations, so apply now to be considered. Click here to view the full agenda.

On May 24, Governor Tim Walz signed into law Minnesota’s new comprehensive data privacy law, the Minnesota Consumer Data Privacy Act (HF 4757 referenced as the MCDPA). The MCDPA goes into effect on July 31, 2025, with some exceptions for colleges and universities (who have until 2029). The MCDPA is similar to other state privacy laws, […]

The New York legislature passed two bills on June 7, 2024 directed at children’s use of online technologies – the Stop Addictive Feeds Exploitation (SAFE) for Kids Act (S7694) that restricts access to addictive algorithmic feeds and the New York Child Data Protection Act (S7695) that bans sites from collecting, using, sharing or selling personal […]

On June 25th, Rhode Island Governor Daniel McKee transmitted without signature (effectively a pocket veto) the Rhode Island Data Transparency and Privacy Protection Act (SB 2500 / HB 7787). The act is based on the Washington Privacy Act model but diverges from the prevalent forms of that model in two ways. First, the act contains a unique […]

By Mike Cloonan, CEO of Sionna Therapeutics, as part of the From The Trenches feature of LifeSciVC An insightful piece on this blog following the JPM healthcare conference noted the “refreshing burst of enthusiasm” in the biotech sector. It’s true

The post Lessons From A Private Funding Round: Science, Relationships, And Experience appeared first on LifeSciVC.